FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078644313> ?p ?o ?g. }

• W2078644313 endingPage "382" @default.
• W2078644313 startingPage "376" @default.
• W2078644313 abstract "What is known and objective Primary immune thrombocytopenia (ITP) is characterized by accelerated platelet destruction, as well as suboptimal platelet production. Thrombopoietin (TPO) receptor agonists bind to and activate human TPO receptor, and have been shown to increase platelet counts. In this study, we assessed the effectiveness and safety of long-term administration of TPO agonist romiplostim in adult and paediatric patients. Methods This is a retrospective observational study that included every ITP patient (adults and children) who received romiplostim since its inclusion in our institutional formulary. Data on patients' demographics, romiplostim doses, platelet counts, use of rescue medication and concurrent therapies were collected. Outcomes for effectiveness evaluation were proportion of patients who achieved a platelet response (platelet count >50 × 109 per litre and double the platelet count at baseline on any scheduled visit, excluding counts obtained within 8 weeks after receipt of rescue medications), proportion of patients who achieved a durable response (platelet responses during 6 or more weeks of the last 8 weeks of treatment), proportion of patients needing rescue medication, proportion of patients able to stop or reduce concurrent treatment and mean number of weekly platelet responses. Safety was assessed on the basis of the incidence of adverse events documented on the patients' medical records. Results and discussion This study enrolled ten adults and four paediatric patients. None of the paediatric patients and one adult patient had been splenectomized (contraindicated in the other adults). In the adult population, eight achieved a response at least once during treatment, and 1 achieved a durable response. Four patients needed rescue medication (mostly intravenous immunoglobulins). Three patients were able to stop concurrent ITP therapies, and the mean number of weekly platelet responses was 6. All four paediatric patients achieved a response at least once during treatment, and three achieved durable responses. Three patients needed rescue medication. The only patient who was receiving concurrent ITP medication was able to stop it, and the mean number of weekly platelet responses was 25. No serious adverse events were registered during treatment in either population. What is new and conclusion The effectiveness of romiplostim was variable with few adult patients achieving a durable response. Our paediatric patients responded better with most achieving a durable response. The treatment was safe for both groups of patients. Studies should be conducted to identify patients more likely to benefit from this treatment." @default.
• W2078644313 created "2016-06-24" @default.
• W2078644313 creator A5012961443 @default.
• W2078644313 creator A5063759770 @default.
• W2078644313 creator A5075958902 @default.
• W2078644313 creator A5078047464 @default.
• W2078644313 creator A5081483250 @default.
• W2078644313 creator A5082744602 @default.
• W2078644313 date "2014-04-04" @default.
• W2078644313 modified "2023-09-26" @default.
• W2078644313 title "The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital" @default.
• W2078644313 cites W1974541132 @default.
• W2078644313 cites W1977189730 @default.
• W2078644313 cites W1979820418 @default.
• W2078644313 cites W1980002878 @default.
• W2078644313 cites W1981693350 @default.
• W2078644313 cites W1984073642 @default.
• W2078644313 cites W1994486978 @default.
• W2078644313 cites W2021830136 @default.
• W2078644313 cites W2025214258 @default.
• W2078644313 cites W2059190713 @default.
• W2078644313 cites W2059418185 @default.
• W2078644313 cites W2070214673 @default.
• W2078644313 cites W2071843728 @default.
• W2078644313 cites W2078397642 @default.
• W2078644313 cites W2079640659 @default.
• W2078644313 cites W2084718852 @default.
• W2078644313 cites W2103710704 @default.
• W2078644313 cites W2104778351 @default.
• W2078644313 cites W2113669085 @default.
• W2078644313 cites W2115876636 @default.
• W2078644313 cites W2119920607 @default.
• W2078644313 cites W2130271496 @default.
• W2078644313 cites W2139745353 @default.
• W2078644313 cites W2144118333 @default.
• W2078644313 cites W2150405273 @default.
• W2078644313 cites W2150724291 @default.
• W2078644313 cites W2153670291 @default.
• W2078644313 cites W4244215862 @default.
• W2078644313 doi "https://doi.org/10.1111/jcpt.12156" @default.
• W2078644313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24702274" @default.
• W2078644313 hasPublicationYear "2014" @default.
• W2078644313 type Work @default.
• W2078644313 sameAs 2078644313 @default.
• W2078644313 citedByCount "5" @default.
• W2078644313 countsByYear W20786443132014 @default.
• W2078644313 countsByYear W20786443132016 @default.
• W2078644313 countsByYear W20786443132017 @default.
• W2078644313 countsByYear W20786443132019 @default.
• W2078644313 countsByYear W20786443132020 @default.
• W2078644313 crossrefType "journal-article" @default.
• W2078644313 hasAuthorship W2078644313A5012961443 @default.
• W2078644313 hasAuthorship W2078644313A5063759770 @default.
• W2078644313 hasAuthorship W2078644313A5075958902 @default.
• W2078644313 hasAuthorship W2078644313A5078047464 @default.
• W2078644313 hasAuthorship W2078644313A5081483250 @default.
• W2078644313 hasAuthorship W2078644313A5082744602 @default.
• W2078644313 hasBestOaLocation W20786443131 @default.
• W2078644313 hasConcept C109159458 @default.
• W2078644313 hasConcept C126322002 @default.
• W2078644313 hasConcept C168563851 @default.
• W2078644313 hasConcept C187212893 @default.
• W2078644313 hasConcept C197934379 @default.
• W2078644313 hasConcept C203092338 @default.
• W2078644313 hasConcept C2776915898 @default.
• W2078644313 hasConcept C2777863708 @default.
• W2078644313 hasConcept C2778715236 @default.
• W2078644313 hasConcept C2780588981 @default.
• W2078644313 hasConcept C28328180 @default.
• W2078644313 hasConcept C2908647359 @default.
• W2078644313 hasConcept C2993327898 @default.
• W2078644313 hasConcept C54355233 @default.
• W2078644313 hasConcept C71924100 @default.
• W2078644313 hasConcept C86803240 @default.
• W2078644313 hasConcept C89560881 @default.
• W2078644313 hasConcept C99454951 @default.
• W2078644313 hasConceptScore W2078644313C109159458 @default.
• W2078644313 hasConceptScore W2078644313C126322002 @default.
• W2078644313 hasConceptScore W2078644313C168563851 @default.
• W2078644313 hasConceptScore W2078644313C187212893 @default.
• W2078644313 hasConceptScore W2078644313C197934379 @default.
• W2078644313 hasConceptScore W2078644313C203092338 @default.
• W2078644313 hasConceptScore W2078644313C2776915898 @default.
• W2078644313 hasConceptScore W2078644313C2777863708 @default.
• W2078644313 hasConceptScore W2078644313C2778715236 @default.
• W2078644313 hasConceptScore W2078644313C2780588981 @default.
• W2078644313 hasConceptScore W2078644313C28328180 @default.
• W2078644313 hasConceptScore W2078644313C2908647359 @default.
• W2078644313 hasConceptScore W2078644313C2993327898 @default.
• W2078644313 hasConceptScore W2078644313C54355233 @default.
• W2078644313 hasConceptScore W2078644313C71924100 @default.
• W2078644313 hasConceptScore W2078644313C86803240 @default.
• W2078644313 hasConceptScore W2078644313C89560881 @default.
• W2078644313 hasConceptScore W2078644313C99454951 @default.
• W2078644313 hasIssue "4" @default.
• W2078644313 hasLocation W20786443131 @default.
• W2078644313 hasLocation W20786443132 @default.
• W2078644313 hasOpenAccess W2078644313 @default.

• next